These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 25249059)
1. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059 [TBL] [Abstract][Full Text] [Related]
2. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189 [TBL] [Abstract][Full Text] [Related]
3. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190 [TBL] [Abstract][Full Text] [Related]
4. Oral versus transdermal selegiline: antidepressant-like activity in rats. Gordon MN; Muller CD; Sherman KA; Morgan DG; Azzaro AJ; Wecker L Pharmacol Biochem Behav; 1999 Jul; 63(3):501-6. PubMed ID: 10418793 [TBL] [Abstract][Full Text] [Related]
5. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I; Youdim MB; Finberg JP J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937 [TBL] [Abstract][Full Text] [Related]
6. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. Mawhinney M; Cole D; Azzaro AJ J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864 [TBL] [Abstract][Full Text] [Related]
7. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Fowler JS; Volkow ND; Logan J; Franceschi D; Wang GJ; MacGregor R; Shea C; Garza V; Pappas N; Carter P; Netusil N; Bridge P; Liederman D; Elkashef A; Rotrosen J; Hitzemann R Life Sci; 2001 May; 68(24):2759-68. PubMed ID: 11400918 [TBL] [Abstract][Full Text] [Related]
8. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Wecker L; James S; Copeland N; Pacheco MA Biol Psychiatry; 2003 Nov; 54(10):1099-104. PubMed ID: 14625153 [TBL] [Abstract][Full Text] [Related]
9. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain. Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477 [TBL] [Abstract][Full Text] [Related]
10. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Hirvonen J; Kailajärvi M; Haltia T; Koskimies S; Någren K; Virsu P; Oikonen V; Sipilä H; Ruokoniemi P; Virtanen K; Scheinin M; Rinne JO Clin Pharmacol Ther; 2009 May; 85(5):506-12. PubMed ID: 19129751 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of platelet monoamine oxidase type B by selegiline. Heinonen EH; Anttila MI; Nyman LM; Pyykkö KA; Vuorinen JA; Lammintausta RA J Clin Pharmacol; 1997 Jul; 37(7):597-601. PubMed ID: 9243352 [TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase B inhibitor, selegiline, reduces Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327 [TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Lamensdorf I; Porat S; Simantov R; Finberg JP Br J Pharmacol; 1999 Feb; 126(4):997-1002. PubMed ID: 10193780 [TBL] [Abstract][Full Text] [Related]
14. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Haberle D; Szökõ E; Magyar K Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347 [TBL] [Abstract][Full Text] [Related]
15. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. Todd KG; Baker GB J Affect Disord; 1995 Dec; 35(3):125-9. PubMed ID: 8749840 [TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Mahmood I Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033 [TBL] [Abstract][Full Text] [Related]
17. Evidence for reduced arterial plasma input, prolonged lung retention and reduced lung monoamine oxidase in smokers. Logan J; Fowler JS Nucl Med Biol; 2005 Jul; 32(5):521-9. PubMed ID: 15982583 [TBL] [Abstract][Full Text] [Related]
18. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151 [TBL] [Abstract][Full Text] [Related]
19. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053 [TBL] [Abstract][Full Text] [Related]
20. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Youdim MB; Tipton KF Parkinsonism Relat Disord; 2002 Mar; 8(4):247-53. PubMed ID: 12039419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]